Novocure

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novocure reports robust Q4 performance and eyes market expansion

Novocure's Q4 2022 performance showcased strong revenue growth, positive clinical outcomes, and ongoing investments in research and development.
Despite facing challenges in achieving positive adjusted EBITDA and addressing analyst inquiries, the company's strengths in innovation and partnerships position it for future success.
Opportunities in driving adoption of TTFields therapy, expanding into new indications, and leveraging partnerships underscore Novocure's growth potential in the oncology market.
With a focus on strategic planning and execution, Novocure aims to continue its trajectory of success, supported by a solid financial foundation and commitment to innovation.

NovoCure excels in Q1 with strong revenue and trial outcomes

NovoCure's Q1 2023 call highlighted strong financial performance, successful trial outcomes, and strategic plans for growth and innovation, while also acknowledging challenges in market expansion and patient growth.

Novocure reports robust Q2 earnings, advances innovative cancer therapies

Novocure's Q2 2023 performance reflects strong revenue growth and a focus on advancing innovative cancer therapies, particularly highlighted by the successful LUNAR trial results.
While facing challenges in regulatory processes and market expansion, Novocure's strategic strengths lie in its leadership in developing novel treatments and commitment to clinical advancement.
The upcoming Phase III trials and strategic initiatives present opportunities for Novocure to solidify its position as a key player in the oncology space and drive future growth.

NovoCure reports robust Q3 earnings, eyes global expansion and clinical milestones

NovoCure's Q3 performance reflects strong revenue growth and progress in clinical trials, particularly in lung cancer and GBM. While facing challenges related to denied payments and upcoming trials, the company remains resilient with exciting opportunities for global expansion and continued success in the oncology market.

NovoCure reports robust Q4 earnings, eyes growth in cancer therapies

NovoCure's Q4 2023 performance reflects strong financial results, progress in clinical trials, and a focus on extending survival in aggressive cancers through innovative therapies.
The company's strengths lie in its leadership in cancer treatment innovation, solid financial position, and commitment to disciplined growth strategies.
Challenges include regulatory approvals, managing cash burn, and maintaining cost efficiency, while opportunities abound in expanding product portfolio and advancing clinical trials for improved patient outcomes.

NovoCure excels in Q1 with record patient adoption and revenue growth

NovoCure's Q1 2024 performance reflects strong patient adoption, revenue growth, and strategic financial decisions to support future expansion and innovation.
While facing challenges related to regulatory processes and market dynamics, NovoCure's focus on clinical advancements and financial stability positions it well for long-term success.
The company's strengths in innovative therapies, positive trial outcomes, and financial resilience offer a solid foundation for seizing growth opportunities and overcoming potential obstacles.

NovoCure reports robust Q2 performance and outlines growth strategies

NovoCure's Q2 performance reflects strong financial results, patient growth, and progress in clinical programs, positioning the company for continued success.
Clear objectives set for 2024 and confidence expressed by executives indicate a strategic focus on growth and innovation in cancer therapy.
While facing challenges in regulatory processes and market competition, NovoCure has opportunities to leverage its strengths in commercialization and clinical development for future expansion.

Novocure reports robust Q3 earnings, eyes growth in cancer treatments

Novocure's Q3 performance reflects solid financial growth and patient adoption, supported by a strong focus on innovative cancer treatments and clinical advancements.
While leadership transitions and reimbursement challenges exist, the company's strategic initiatives and pipeline progress position them well for future success and market expansion.
Overall, Novocure's commitment to extending survival in aggressive cancers, coupled with operational improvements and market opportunities, underpin a positive outlook for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novocure has a novel and original way to treat cancer. However, the company's financial results haven't been great.

Is Novocure Stock a Buy?

The cancer treatment device developer released its latest set of quarterly results. These were a mixed bag, as it notched a beat on earnings but missed on revenue.

Why Novocure Stock Was Sick Today

NovoCure Limited (NASDAQ:NVCR ) Q3 2023 Earnings Conference Call October 26, 2023 8:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Pritesh Shah - Chief Growth Officer Uri Weinberg - Chief Innovation Officer Conference Call Participants Jonathan Chang - Leerink Partners Lei Huang - Wells Fargo Emily Bodnar - H.C. Wainwright Operator Welcome to the NovoCure Q3 2023 Earnings Conference Call.

NovoCure Limited (NVCR) Q3 2023 Earnings Call Transcript

NovoCure (NVCR) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.25 per share a year ago.

NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2023.

Novocure Reports Third Quarter 2023 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid. Novocure will present three new posters on Tumor Treating Fields (TTFields) therapy, including an analysis of patient-reported health-related global and functional quality of life scores from the randomized phase 3 LUNAR clinical trial in metastatic non-small cell lung cancer (NSCLC). The new analysis of d.

Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. “We look forward to collaborating with Stanford Medicine to establish a research.

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced that it will report financial results for the third quarter 2023 on October 26, 2023, before the U.S. financial markets open.

Novocure to Report Third Quarter 2023 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTFields) therapy, including new insights about methods to optimize TTFields intensities delivered at the target tumor during treatment. Highlights of Novocure's poster presentatio.

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

NovoCure doesn't have any direct competitors for its anti-cancer device. The product could see its indications expanded into various other niches.

3 Things About NovoCure That Smart Investors Know

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore. Novocure will take part in presentations and symposia throughout the event and will exhibit several posters exploring the use of Tumor Treating Fields (TTFields) therapy in the treatment of lung cancer, including a new post-hoc analysis of.

Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

Revance Therapeutics

SAGE Therapeutics

The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA approval and positive results for therapies, pharmaceuticals, and trials greatly influences the outlook for companies, especially ones with small market cap share price.

3 Healthcare Stocks to Sell in September Before They Crash & Burn

One of NovoCure's late-stage clinical trials didn't turn out well. There are serious questions about the cost effectiveness of its product.

Down 31% in 1 Day, What's Next for NovoCure Stock?

On Monday, Novocure announced a key phase 3 trial evaluating its Tumor Treating Fields (TTFields) therapy in treating platinum-resistant ovarian cancer failed to meet its primary endpoint. The company has vowed to continue researching the therapy, noting there are limited treatment options for this aggressive cancer.

Why Novocure Stock Fell 24.4% This Week

NovoCure's treatment for ovarian cancer failed to prove it was effective in a late-stage trial. It's a big blow for a company whose business isn't in terribly great shape.

Is NovoCure's Stock Headed for a Free Fall?

LOS ANGELES, CA / ACCESSWIRE / August 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer (NSCLC) following progression on or after platinum-based therapy have been published in The Lancet Oncology. As presented at the 2023 American Society of Clinical Oncology Annual Meeting, the LUNAR tr.

Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

LOS ANGELES, CA / ACCESSWIRE / August 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm

Novocure (NVCR) shares plunged 37.5% on Monday after the provider of cancer-fighting treatments reported a Phase 3 trial of its Tumor Treating Fields (TTFields) therapy for ovarian cancer patients failed to meet its goal.

Novocure Shares Plunge After Its Ovarian Cancer Treatment Fails to Meet Goal

Shares of innovative biotechnology firm Novocure (NASDAQ: NVCR ) cratered badly, losing 30% on Monday morning before fading even further in the early afternoon session. Unfortunately, the company — which specializes in a tumor-treating technology — failed its Phase 3 trial targeting specific chemotherapy-resistant ovarian cancer patients.

Why Is Novocure (NVCR) Stock Down 30% Today?

NovoCure's tumor treating fields therapy didn't meet the primary endpoint in a phase 3 study targeting ovarian cancer. The company's analysis pointed to a potential benefit for TTFields in treating ovarian cancer patients with only one prior therapy.

Why NovoCure Stock Is Crashing Today

Novocure (NASDAQ:NVCR) shares are down nearly a third Monday after a Phase 3 study of its Tumor Treating Fields therapy was reported to have failed.  The stock hit a 52-week low after the company announced the study of patients with recurrent ovarian cancer did not meet its primary endpoint of overall survival.

Novocure stock plummets after Phase 3 cancer trial fails to reach desired endpoint

Novocure said Monday its cancer treatment failed to make a difference for ovarian cancer patients, and NVCR stock plummeted.

Novocure Plummets 34% After Its Cancer Treatment Fails In Ovarian Cancer

Shares of Novocure Ltd. NVCR, -0.77% dropped 37% premarket on Monday after the Swiss oncology company said a late-stage trial of Tumor Treating Fields with paclitaxel failed to meet its primary endpoint of overall survival in patients with ovarian cancer.

Novocure shares plunge after ovarian cancer study failure

Novocure said on Monday its therapy failed in a late-stage trial to meet the main goal of improving survival rates in patients with a type of ovarian cancer.

News for Novocure Stock (NVCR)